{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:38:51Z","timestamp":1793882331833,"version":"4.7.0"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Monkeypox (mpox) is a zoonotic illness caused by the monkeypox virus (MPXV), with higher health concerns among people who are pregnant, children, and persons who are immunocompromised, including people with untreated and advanced HIV disease. Significant progress has been made in developing vaccines against mpox, yet critical challenges and limitations persist in ensuring their effectiveness, safety, and accessibility. The pertinence of this review is highlighted by the World Health Organization\u2019s declaration of a global health emergency on August 14, 2024, due to the recent mpox outbreak, underscoring the critical necessity for effective vaccine solutions in the face of a rapidly evolving virus. Here, we comprehensively analyze various vaccine platforms utilized in mpox prevention, including attenuated and non-replicating virus vaccines, viral vector-based vaccines, recombinant protein vaccines, and DNA and mRNA vaccines. We evaluate the advantages and limitations of each platform, highlighting the urgent need for ongoing research and innovation to enhance vaccine efficacy and safety. Recent advancements, such as incorporating immunostimulatory sequences, improved delivery systems, and developing polyvalent vaccines, are explored for their potential to offer broader protection against diverse orthopoxvirus strains. This work underscores the need to optimize currently available vaccines and investigate novel vaccination strategies to address future public health emergencies effectively. By focusing on these advanced methodologies, we aim to contribute to the development of robust and adaptable vaccine solutions for mpox and other related viral threats.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1456060","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:34:00Z","timestamp":1728606840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Advancements in monkeypox vaccines development: a critical review of emerging technologies"],"prefix":"10.3389","volume":"15","author":[{"given":"Igor","family":"Garcia-Atutxa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mondragon-Teran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Huerta-Saquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Villanueva-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.37201\/req\/059.202","article-title":"Monkeypox in humans: a new outbreak","volume":"35","author":"Mart\u00edn-Delgado","year":"2022","journal-title":"Rev Esp Quimioter: publicacion oficial de la Sociedad Espanola de Quimioterapia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"105662","DOI":"10.1016\/j.jcv.2024.105662","article-title":"Human monkeypox virus: Epidemiologic review and research progress in diagnosis and treatment","volume":"171","author":"Sun","year":"2024","journal-title":"J Clin Virol"},{"key":"B3","unstructured":"Monkeypox: experts give virus variants new names2022"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010141","article-title":"The changing epidemiology of human monkeypox-A potential threat? A systematic review","volume":"16","author":"Bunge","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2208860","article-title":"Monkeypox","volume":"387","author":"Gessain","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.19.242347","article-title":"Modelling human-to-human transmission of monkeypox","volume":"98","author":"Grant","year":"2020","journal-title":"Bull World Health Organ"},{"key":"B7","volume-title":"Africa Centres for Disease Control and Prevention (AfricaCDC)","year":"2024"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29029","article-title":"Intra- and interhost genomic diversity of monkeypox virus","volume":"95","author":"Taouk","year":"2023","journal-title":"J Med Virol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-75-6-1303","article-title":"Evidence for recent genetic variation in monkeypox viruses","volume":"75","author":"Douglass","year":"1994","journal-title":"J Gen Virol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/pathogens12010146","article-title":"Clinical characteristics of human Mpox (Monkeypox) in 2022: A systematic review and meta-analysis","volume":"12","author":"Liu","year":"2023","journal-title":"Pathogens"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/vaccines11061093","article-title":"The global monkeypox (Mpox) outbreak: A comprehensive review","volume":"11","author":"Srivastava","year":"2023","journal-title":"Vaccines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00062-23","article-title":"An APOBEC3 mutational signature in the genomes of human-infecting orthopoxviruses","volume":"8","author":"Forni","year":"2023","journal-title":"mSphere"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/5584_2022_747","article-title":"Clinical manifestations of Monkeypox","volume":"1410","author":"Abaza","year":"2023","journal-title":"Adv Exp Med Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207323","article-title":"Monkeypox virus infection across 16 countries - April-June 2022","volume":"387","author":"Thornhill","year":"2022","journal-title":"Reply N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130118","article-title":"Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo","volume":"20","author":"Kugelman","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.002","article-title":"Monkeypox emergency: Urgent questions and perspectives","volume":"185","author":"Rothenburg","year":"2022","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1600-065X.2008.00691.x","article-title":"Monkeypox virus and insights into its immunomodulatory proteins","volume":"225","author":"Weaver","year":"2008","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2022-cme-mpox","article-title":"Human monkeypox infection","volume":"22","author":"Daunt","year":"2022","journal-title":"Clin Med (Lond)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.1.130-147.1994","article-title":"Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network","volume":"68","author":"Schmelz","year":"1994","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.57.030502.091037","article-title":"Vaccinia virus motility","volume":"57","author":"Smith","year":"2003","journal-title":"Annu Rev Microbiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"104424","DOI":"10.1016\/j.ebiom.2022.104424","article-title":"The land-scape of immune response to monkeypox virus","volume":"87","author":"Li","year":"2023","journal-title":"EBioMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade6360","article-title":"Structure of monkeypox virus DNA polymerase holoenzyme","volume":"379","author":"Peng","year":"2023","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"102855","DOI":"10.1016\/j.jaut.2022.102855","article-title":"The 2022 outbreak and the pathobiology of the monkeypox virus","volume":"131","author":"Kumar","year":"2022","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28643","article-title":"Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II","volume":"95","author":"Criscuolo","year":"2023","journal-title":"J Med Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.08.019","article-title":"Immunity from smallpox vaccine persists for decades: A longitudinal study","volume":"121","author":"Taub","year":"2008","journal-title":"Am J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215201","article-title":"Vaccine effectiveness of JYNNEOS against Mpox disease in the United States","volume":"388","author":"Deputy","year":"2023","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2023.08.376","article-title":"Estimated effectiveness of JYNNEOS vaccine in preventing Mpox: A multijurisdictional case-control study \u2014 United States, August 19, 2022\u2013March 31, 2023","volume":"82","author":"Huber","year":"2023","journal-title":"Ann Emergency Med"},{"key":"B28","first-page":"78","article-title":"Mpox: rapid evidence review","volume":"108","author":"Saguil","year":"2023","journal-title":"Am Fam Physician"},{"key":"B29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/life13030787","article-title":"Evaluating the immunogenicity and safety of a smallpox vaccine to Monkeypox in healthy Japanese adults: A single-arm study","volume":"13","author":"Tomita","year":"2023","journal-title":"Life (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2196\/46955","article-title":"Efficacy and safety of the smallpox vaccine for postexposure prophylaxis in monkeypox: protocol for an open-labeled, single-armed study","volume":"12","author":"Yano","year":"2023","journal-title":"JMIR Res Protoc"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000000550","article-title":"Mpox vaccination in global perspective: priorities and challenges","volume":"85","author":"Rana","year":"2023","journal-title":"Ann Med Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14760584.8.1.13","article-title":"IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine","volume":"8","author":"Kennedy","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00642-3","article-title":"Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity","volume":"39","author":"P\u00f6yh\u00f6nen","year":"2019","journal-title":"J Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.135","article-title":"Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques","volume":"29","author":"Denzler","year":"2011","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000000861","article-title":"Concerns over cardiovascular manifestations associated with monkeypox immunization: a literature review","volume":"85","author":"Shrestha","year":"2023","journal-title":"Ann Med Surg"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/vaccines10091419","article-title":"Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines","volume":"10","author":"Abdelaal","year":"2022","journal-title":"Vaccines"},{"key":"B39","unstructured":"Mpox Vaccine Tracker - List of vaccine candidates in research & development2023"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583077","article-title":"Emerging concepts and technologies in vaccine development","volume":"11","author":"Brisse","year":"2020","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S112045","article-title":"Optimization, formulation, and characterization of multiflavonoids-loaded flavanosome by bulk or sequential technique","volume":"11","author":"Karthivashan","year":"2016","journal-title":"IJN"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003850","article-title":"BoHV-4-based vector single heterologous antigen delivery protects STAT1(-\/-) mice from Monkeypoxvirus lethal challenge","volume":"9","author":"Franceschi","year":"2015","journal-title":"PloS Negl Trop Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/v15020356","article-title":"Single dose of recombinant chimeric Horsepox virus (TNX-801) vaccination protects macaques from lethal Monkeypox challenge","volume":"15","author":"Noyce","year":"2023","journal-title":"Viruses"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1016\/j.vaccine.2010.05.023","article-title":"Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection","volume":"28","author":"Rudraraju","year":"2010","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/v8050139","article-title":"Deletion of A44L, A46R and C12L vaccinia virus genes from the MVA genome improved the vector immunogenicity by modifying the innate immune response generating enhanced and optimized specific T-cell responses","volume":"8","author":"Holgado","year":"2016","journal-title":"Viruses"},{"key":"B49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vaccine.2015.11.028","article-title":"Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter","volume":"34","author":"Alharbi","year":"2016","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3390\/vaccines10122010","article-title":"Multi-Epitope Vaccine Design against Monkeypox Virus via Reverse Vaccinology Method Exploiting Immunoinformatic and Bioinformatic Approaches","volume":"10","author":"Bhattacharya","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2022.2125441","article-title":"An integrative reverse vaccinology, immunoinformatic, docking and simulation approaches towards designing of multi-epitopes based vaccine against monkeypox virus","volume":"41","author":"Ullah","year":"2023","journal-title":"J Biomol Struct Dyn"},{"key":"B52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","article-title":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","volume":"170","author":"Pollet","year":"2021","journal-title":"Advanced Drug Delivery Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2017.10.002","article-title":"Recent advances in vaccine technologies","volume":"48","author":"Francis","year":"2018","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.030","article-title":"A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge","volume":"28","author":"Buchman","year":"2010","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.018","article-title":"Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus","volume":"38","author":"Xiao","year":"2020","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1203410","article-title":"Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01854-07","article-title":"Vaccination of BALB\/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge","volume":"82","author":"Berhanu","year":"2008","journal-title":"J Virol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s000180050330","article-title":"Immune responses to DNA vaccines","volume":"55","author":"Kowalczyk","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00271-6","article-title":"DNA and RNA-based vaccines: principles, progress and prospects","volume":"18","author":"Leitner","year":"1999","journal-title":"Vaccine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01140.x","article-title":"DNA vaccines: a review","volume":"253","author":"Liu","year":"2003","journal-title":"J Intern Med"},{"key":"B61","article-title":"DNA vaccines: Fundamentals and practice","volume-title":"En: Methods in Microbiology","author":"Corr","year":"2002"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2741\/1872","article-title":"DNA vaccines for cancer","volume":"11","author":"Shaw","year":"2006","journal-title":"Front Biosci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1286-4579(99)80009-4","article-title":"DNA vaccines for viral diseases","volume":"1","author":"Davis","year":"1999","journal-title":"Microbes Infect"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7519(03)00056-0","article-title":"Technical and regulatory hurdles for DNA vaccines","volume":"33","author":"Donnelly","year":"2003","journal-title":"Int J Parasitol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.020","article-title":"Incorporation of\u00a0immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine\u00a0enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice","volume":"29","author":"Wu","year":"2011","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-002-0144-z","article-title":"DNA immunization\u2013a new chance in vaccine research","volume":"191","author":"Henke","year":"2002","journal-title":"Med Microbiol Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1159\/000053993","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2000","journal-title":"Intervirology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950018517","article-title":"Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection","volume":"10","author":"Martin","year":"1999","journal-title":"Hum Gene Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/infdis\/jiq017","article-title":"Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge","volume":"203","author":"Hirao","year":"2011","journal-title":"J Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.11.017","article-title":"Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge","volume":"25","author":"Hooper","year":"2007","journal-title":"Vaccine"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01504-21","article-title":"A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge","volume":"96","author":"Mucker","year":"2022","journal-title":"J Virol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1203355","article-title":"Design, evaluation, and immune simulation of potentially universal multi-epitope mpox vaccine candidate: focus on DNA vaccine","volume":"14","author":"Rcheulishvili","year":"2023","journal-title":"Front Microbiol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112816","article-title":"Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches","volume":"14","author":"Tan","year":"2023","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/12.18.7057","article-title":"Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs","volume":"12","author":"Krieg","year":"1984","journal-title":"Nucl Acids Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/v15030668","article-title":"Research advances on the stability of mRNA vaccines","volume":"15","author":"Cheng","year":"2023","journal-title":"Viruses"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1711.2005.01331.x","article-title":"Immune responses to dsRNA: implications for gene silencing technologies","volume":"83","author":"Karpala","year":"2005","journal-title":"Immunol Cell Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2011.01.034","article-title":"RNA species generated in vaccinia virus infected cells activate cell type-specific MDA5 or RIG-I dependent interferon gene transcription and PKR dependent apoptosis","volume":"413","author":"Myskiw","year":"2011","journal-title":"Virology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018961","article-title":"Advancing mRNA technologies for therapies and vaccines: An African context","volume":"13","author":"Kairuz","year":"2022","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/15476286.2022.2055923","article-title":"Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases","volume":"19","author":"Rouf","year":"2022","journal-title":"RNA Biol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"B86","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/vaccines7020037","article-title":"A comparison of plasmid DNA and mRNA as vaccine technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.02.033","article-title":"The relative immunogenicity\u00a0of\u00a0DNA vaccines delivered by the intramuscular needle injection, electroporation and\u00a0gene gun methods","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J Pharm Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.3390\/v14091905","article-title":"Virus-like particles as nanocarriers for intracellular delivery of biomolecules and compounds","volume":"14","author":"He","year":"2022","journal-title":"Viruses"},{"key":"B90","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/pharmaceutics13060877","article-title":"Protamine-based strategies for RNA transfection","volume":"13","author":"Jarzebska","year":"2021","journal-title":"Pharmaceutics"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol Cell Toxicol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.20883\/medical.e750","article-title":"Multi-epitope mRNA vaccine design that exploits variola\u00a0virus and Monkeypox virus proteins for elicitation of long-lasting humoral and cellular protection against severe disease","volume":"91","author":"Kova\u010di\u0107","year":"2022","journal-title":"JMS"},{"key":"B95","doi-asserted-by":"publisher","first-page":"109270","DOI":"10.1016\/j.cclet.2023.109270","article-title":"An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus","volume":"35","author":"Tian","year":"2023","journal-title":"Chin Chem Lett"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2204151","DOI":"10.1080\/22221751.2023.2204151","article-title":"Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge","volume":"12","author":"Zeng","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2378-x","article-title":"Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B98","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-023-01432-5","article-title":"Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus","volume":"8","author":"Sang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3540","article-title":"An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge","volume":"15","author":"Freyn","year":"2023","journal-title":"Sci Transl Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1101\/2022.11.19.517190","article-title":"Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge","author":"Hou","year":"2022"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-023-00792-5","article-title":"Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens","volume":"33","author":"Fang","year":"2023","journal-title":"Cell Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/vaccines12040385","article-title":"A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models","volume":"12","author":"Su","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00740-09","article-title":"Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses","volume":"78","author":"Reyes-Sandoval","year":"2010","journal-title":"Infect Immun"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1215","article-title":"A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus","volume":"24","author":"Moutaftsi","year":"2006","journal-title":"Nat Biotechnol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S3687","article-title":"ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile","volume":"4","author":"Nalca","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1132250","article-title":"Insights into monkeypox pathophysiology, global prevalence, clinical manifestation and treatments","volume":"14","author":"Niu","year":"2023","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1001\/jama.294.21.2734","article-title":"Adverse events associated with smallpox vaccination in the United\u00a0States, January-October 2003","volume":"294","author":"Casey","year":"2005","journal-title":"JAMA"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3390\/vaccines10111971","article-title":"Comparison of biological, pharmacological characteristics, indications, contraindications and adverse effects of JYNNEOS and ACAM2000 monkeypox vaccines","volume":"10","author":"Meo","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7122e1","article-title":"Use of JYNNEOS (Smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the advisory committee on immunization practices \u2014 United states, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B111","doi-asserted-by":"publisher","first-page":"297","DOI":"10.18433\/jpps33138","article-title":"Monkeypox: virology, pathophysiology, clinical characteristics, epidemiology, vaccines, diagnosis, and treatments","volume":"25","author":"Soheili","year":"2022","journal-title":"J Pharm Pharm Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: an attenuated smallpox vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"key":"B113","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.virol.2007.02.041","article-title":"Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate","volume":"366","author":"Earl","year":"2007","journal-title":"Virology"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.095","article-title":"Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination","volume":"26","author":"Grosenbach","year":"2008","journal-title":"Vaccine"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03481-12","article-title":"Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques","volume":"87","author":"Hatch","year":"2013","journal-title":"J Virol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2016.417","article-title":"A single vaccination of nonhuman primates with highly attenuated smallpox vaccine, LC16m8, provides long-term protection against monkeypox","volume":"70","author":"Iizuka","year":"2017","journal-title":"Jpn J Infect Dis"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02174-10","article-title":"Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges","volume":"85","author":"Keckler","year":"2011","journal-title":"J Virol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/vaccines8030396","article-title":"IMVAMUNE\u00ae and ACAM2000\u00ae Provide different protection against disease when administered postexposure in an intranasal monkeypox challenge prairie dog model","volume":"8","author":"Keckler","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.05.058","article-title":"Comparative efficacy of intramuscular and scarification routes of administration of live smallpox vaccine in a murine challenge model","volume":"35","author":"Phelps","year":"2017","journal-title":"Vaccine"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.049","article-title":"Co-administration of tecovirimat and ACAM2000TM in non-human primates: Effect of\u00a0tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal\u00a0monkeypox virus challenge","volume":"38","author":"Russo","year":"2020","journal-title":"Vaccine"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00689-09","article-title":"Expansion, reexpansion, and recall-like expansion of Vgamma2Vdelta2 T cells in smallpox vaccination and monkeypox virus infection","volume":"83","author":"Shao","year":"2009","journal-title":"J Virol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2278900","article-title":"Non-replicating vaccinia virus NTV as an effective next-generation smallpox and monkeypox vaccine: evidence from mouse and rhesus monkey models","volume":"12","author":"Chu","year":"2023","journal-title":"Emerging Microbes Infections"},{"key":"B124","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/vaccines12070776","article-title":"Enhanced immune responses in mice by combining the mpox virus B6R-protein and aluminum hydroxide-CpG vaccine adjuvants","volume":"12","author":"Li","year":"2024","journal-title":"Vaccines"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.02.027","article-title":"Rapid and highly\u00a0potent\u00a0humoral responses to mpox nanovaccine candidates adjuvanted by\u00a0thermostable scaffolds","volume":"42","author":"Yan","year":"2024","journal-title":"Vaccine"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01715-7","article-title":"Rational design of a \u2018two-in-one\u2019 immunogen DAM drives potent immune response against mpox virus","volume":"25","author":"Wang","year":"2024","journal-title":"Nat Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"105974","DOI":"10.1016\/j.antiviral.2024.105974","article-title":"An mpox quadrivalent mRNA vaccine protects mice from lethal vaccinia virus challenge","volume":"230","author":"Li","year":"2024","journal-title":"Antiviral Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"114269","DOI":"10.1016\/j.celrep.2024.114269","article-title":"Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus","volume":"43","author":"Ye","year":"2024","journal-title":"Cell Rep"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.cell.2024.01.017","article-title":"A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease","volume":"187","author":"Zuiani","year":"2024","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1456060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:34:05Z","timestamp":1728606845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1456060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":129,"alternative-id":["10.3389\/fimmu.2024.1456060"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1456060","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"article-number":"1456060"}}